PTC Therapeutics, Inc. (PTCT) financial statements (2020 and earlier)

Company profile

Business Address 100 CORPORATE COURT
SOUTH PLAINFIELD, NJ 07080-2449
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments687228191232339315142
Cash and cash equivalents28816911258585015
Short-term investments3995879173281265127
Receivables56684025114 
Inventory, net of allowances, customer advances and progress billings1916112  
Inventory1916112   
Other undisclosed current assets18973643
Total current assets:779321249261356324145
Noncurrent Assets
Operating lease, right-of-use asset14
Property, plant and equipment221387997
Intangible assets, net (including goodwill)793783133   
Goodwill8282     
Intangible assets, net (excluding goodwill)711701133    
Regulated entity, other noncurrent assets    3  
Other undisclosed noncurrent assets16211000
Total noncurrent assets:844798143812107
TOTAL ASSETS:1,6241,119392269368333152
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1591287649452912
Accounts payable1061561241
Accrued liabilities13224486 
Employee-related liabilities392818141195
Other undisclosed accounts payable and accrued liabilities977339251496
Deferred revenue8
Debt2512    0
Deferred revenue and credits4 031
Contract with customer, liability4
Other liabilities8421   
Other undisclosed current liabilities3519     
Total current liabilities:2361678250453213
Noncurrent Liabilities
Long-term debt and lease obligation2941411459895  
Long-term debt, excluding current maturities2941411459895  
Liabilities, other than long-term debt50044282222
Deferred revenue and credits82   
Deferred revenue3
Contract with customer, liability10
Deferred tax liabilities, net122     
Deferred income tax liabilities131
Other liabilities9000222
Business combination, contingent consideration, liability356310    
Other undisclosed noncurrent liabilities 18     
Total noncurrent liabilities:7946021531009722
Total liabilities:1,0297682351501423515
Stockholders' equity
Stockholders' equity attributable to parent594351156120226298137
Common stock0000000
Additional paid in capital1,7951,288967856820722465
Accumulated other comprehensive income (loss)(11)14(1)(1)(1)0
Accumulated deficit(1,190)(939)(814)(735)(593)(423)(329)
Total stockholders' equity:594351156120226298137
TOTAL LIABILITIES AND EQUITY:1,6241,119392269368333152

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues30726519483372535
Revenue, net19483372535
Cost of revenue
(Cost of Goods and Services Sold)
(12)(2)(5)    
Gross profit:29526319083372535
Operating expenses(548)(380)(259)(215)(204)(125)(80)
Other undisclosed operating income1225    
Operating loss:(241)(116)(64)(132)(167)(99)(45)
Nonoperating income (expense)250(1)(1)(0)(0)0
Foreign currency transaction gain, before tax1200    
Other nonoperating income (expense)140(1)(1)(0)(0)0
Interest and debt expense(1)(1)(0)(0)(0) (0)
Other undisclosed loss from continuing operations before equity method investments, income taxes(23)(12)(12)    
Loss from continuing operations before equity method investments, income taxes:(240)(128)(78)(134)(168)(100)(45)
Other undisclosed income (loss) from continuing operations before income taxes   (8)(2)1(6)
Loss from continuing operations before income taxes:(240)(128)(78)(142)(170)(98)(52)
Income tax expense (benefit)(12)0(1)(1)(0)5 
Loss before gain (loss) on sale of properties:(252)(128)(79)(142)(170)(94)(52)
Other undisclosed net loss      (15)
Net loss:(252)(128)(79)(142)(170)(94)(66)
Other undisclosed net income attributable to parent      15
Net loss attributable to parent:(252)(128)(79)(142)(170)(94)(52)
Preferred stock dividends and other adjustments      3
Other undisclosed net loss available to common stockholders, basic      (18)
Net loss available to common stockholders, diluted:(252)(128)(79)(142)(170)(94)(66)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(252)(128)(79)(142)(170)(94)(66)
Other comprehensive income (loss)(12)(3)5 (0)(1)0
Comprehensive loss:(264)(131)(74)(142)(171)(94)(66)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   (0) (0)15
Comprehensive loss, net of tax, attributable to parent:(264)(131)(74)(142)(171)(95)(52)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: